U.S. market Closed. Opens in 1 day 11 hours 40 minutes

AKRO | Akero Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 28.09 - 29.76
52 Week Range 15.32 - 37.00
Beta -0.87
Implied Volatility 60.01%
IV Rank 41.50%
Day's Volume 1,441,329
Average Volume 574,404
Shares Outstanding 69,799,100
Market Cap 2,047,905,594
Sector Healthcare
Industry Biotechnology
IPO Date 2019-06-20
Valuation
Profitability
Growth
Health
P/E Ratio -7.76
Forward P/E Ratio N/A
EPS -3.78
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 60
Country USA
Website AKRO
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
*Chart delayed
Analyzing fundamentals for AKRO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see AKRO Fundamentals page.

Watching at AKRO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on AKRO Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙